| Literature DB >> 27087480 |
Glenn Merlino1, Meenhard Herlyn2, David E Fisher3, Boris C Bastian4, Keith T Flaherty5, Michael A Davies6, Jennifer A Wargo6, Clara Curiel-Lewandrowski7, Michael J Weber8, Sancy A Leachman9, Maria S Soengas10, Martin McMahon11, J William Harbour12, Susan M Swetter13, Andrew E Aplin14, Michael B Atkins15, Marcus W Bosenberg16, Reinhard Dummer17, Jeffrey E Gershenwald6, Allan C Halpern18, Dorothee Herlyn2, Giorgos C Karakousis19, John M Kirkwood20, Michael Krauthammer21, Roger S Lo22, Georgina V Long23, Grant McArthur24, Antoni Ribas22, Lynn Schuchter19, Jeffrey A Sosman25, Keiran S Smalley26, Patricia Steeg27, Nancy E Thomas28, Hensin Tsao29, Thomas Tueting30, Ashani Weeraratna2, George Xu19, Randy Lomax31, Alison Martin31, Steve Silverstein31, Tim Turnham31, Ze'ev A Ronai32.
Abstract
The Melanoma Research Foundation (MRF) has charted a comprehensive assessment of the current state of melanoma research and care. Intensive discussions among members of the MRF Scientific Advisory Council and Breakthrough Consortium, a group that included clinicians and scientists, focused on four thematic areas - diagnosis/early detection, prevention, tumor cell dormancy (including metastasis), and therapy (response and resistance). These discussions extended over the course of 2015 and culminated at the Society of Melanoma Research 2015 International Congress in November. Each of the four groups has outlined their thoughts as per the current status, challenges, and opportunities in the four respective areas. The current state and immediate and long-term needs of the melanoma field, from basic research to clinical management, are presented in the following report.Entities:
Keywords: dormancy; early diagnosis; melanoma; metastasis; prevention; therapy
Mesh：
Year: 2016 PMID： 27087480 PMCID： PMC5228487 DOI： 10.1111/pcmr.12475
Source DB: PubMed Journal: Pigment Cell Melanoma Res ISSN： 1755-1471 Impact factor: 4.693